# Development of a highly sensitive and specific POCT testing asthma triggering allergic IgE

> **NIH NIH R43** · ALLERDIA INC · 2023 · $275,740

## Abstract

Abstract
 The overall goal of this project is to develop and eventually commercialize a novel point-of-care test capable
of rapidly and highly accurately detecting allergic IgE to environmental allergens as an approach to promote
healthy living and reduce minority health disparities. The burden of asthma in the US falls disproportionately on
Black, Hispanic and American Indian/Native Alaskans/Asians. These minority groups have the highest asthma
rates, deaths and hospitalizations. IgE-mediated allergic asthma is the major type of asthma, consisting of ~75%
of all the asthmas. The most relevant allergens triggering IgE-mediated allergic asthma are environmental
allergens that disproportionately impact the socioeconomically disadvantaged population and minorities due to
their relatively constraint living conditions, lower available resources and limited access to healthcare, leading to
the existing health disparities. Therefore, a more accurate, convenient, low-cost, rapid and point-of-care
enabled IgE test capable of rapidly and accurately identifying allergic IgE by overcoming false positivity of the
current IgE tests would be a key component in efforts to enhance healthy living and reduce minority health
disparities, but such a point-of-care enabled IgE test is not currently available and yet to be developed. Under
such background we propose to develop a novel IgE testing approach capable of rapidly and accurately detecting
allergic IgE against the common allergens associated with allergic asthma triggering to address the health
disparity issue, using Allerdia’s proprietary Reverse Lateral Flow ImmunoAssay (R-LFIA) technology platform.
In Aim 1, we will individually establish a simplex format of R-LFIA testing IgE commonly associated with asthma
triggering by developing R-LFIA testing IgE specific for allergens of cat, dog, house-dust mite, cockroach,
common pollen, birch, and selected molds (Penicillium notatum, Aspergillus fumigatus, Cladosporium herbarum,
and Alternaria alternata) with high test sensitivity and specificity. In Aim 2, we will develop a point-of-care
enabled rapid test device with multiplex capacity to simultaneously detect allergic IgE responsible for triggering
of allergic asthmas using single sample. Accomplishment of the proposed Aims will pave the way for a
prospective clinical investigation and application of this novel IgE testing in determining the responsible
environmental allergen-specific IgE triggering allergic asthma in a rapid fashion with point-of-care capacity.

## Key facts

- **NIH application ID:** 10600767
- **Project number:** 1R43HL167289-01
- **Recipient organization:** ALLERDIA INC
- **Principal Investigator:** Ke Zhang
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $275,740
- **Award type:** 1
- **Project period:** 2023-02-01 → 2024-07-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10600767

## Citation

> US National Institutes of Health, RePORTER application 10600767, Development of a highly sensitive and specific POCT testing asthma triggering allergic IgE (1R43HL167289-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10600767. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*